Longitudinal increase in albumin–bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis
Akira Sakamaki,
Masaaki Takamura,
Norihiro Sakai,
Yusuke Watanabe,
Yoshihisa Arao,
Naruhiro Kimura,
Toru Setsu,
Hiroyuki Abe,
Takeshi Yokoo,
Hiroteru Kamimura,
Shunsuke Tsubata,
Nobuo Waguri,
Toru Ishikawa,
Hirokazu Kawai,
Soichi Sugitani,
Tomomi Sato,
Kazuhiro Funakoshi,
Masashi Watanabe,
Kentarou Igarashi,
Kenya Kamimura,
Atsunori Tsuchiya,
Yutaka Aoyagi and
Shuji Terai
PLOS ONE, 2022, vol. 17, issue 2, 1-13
Abstract:
Due to the developments in the treatment for hepatitis, it is possible to prevent the progression of liver fibrosis and improve patients’ prognosis even if it has already led to liver cirrhosis (LC). Consequently, a two-step study was conducted. To begin with, a retrospective study was conducted to identify the potential predictors of non-malignancy-related mortality from LC. Then, we prospectively analyzed the validity of these parameters as well as their association with patients’ quality of life. In the retrospective study, 89 cases were included, and the multivariate Cox regression analysis indicated that age (P = 0.012), model for end-stage liver disease (MELD) score (P = 0.012), and annual rate of change of the albumin–bilirubin (ALBI) score (P
Date: 2022
References: View complete reference list from CitEc
Citations:
Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263464 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 63464&type=printable (application/pdf)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0263464
DOI: 10.1371/journal.pone.0263464
Access Statistics for this article
More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().